SCHEMBL2909237

SCHEMBL2909237

COC(=O)C(C)(C)Oc1cc(Br)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KMT2A Q03164 1/20 0.43
HPGD P15428 3/20 0.43
MAPT P10636 2/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
RECQL P46063 1/20 0.42
FBP1 P09467 1/20 0.42
ALDH1A1 P00352 2/20 0.40
ACLY P53396 2/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
AAK1 Q2M2I8 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23124788 0.87 FBP1 (0.41) SMN1; SMN2KMT2AHPGDMAPTPOLB
SCHEMBL30093499 0.87 FBP1 (0.41) SMN1; SMN2KMT2AHPGDMAPTPOLB
SCHEMBL23849504 0.84 PPARA (0.47) LMNAKMT2AHPGDMAPTPOLB
SCHEMBL4399378 0.80 RAB9A (0.50) LMNASMN1; SMN2KMT2AHPGDMAPT
SCHEMBL3988132 0.79 AAK1 (0.44) LMNASMN1; SMN2KMT2AMAPTGAA
SCHEMBL30736748 0.78 PTGDR2 (0.43) LMNASMN1; SMN2KMT2AMAPTALDH1A1
SCHEMBL18580869 0.77 NPSR1 (0.45) LMNASMN1; SMN2KMT2AHPGDMAPT
SCHEMBL2424582 0.75 LMNA (0.38) LMNASMN1; SMN2KMT2AHPGDMAPT
SCHEMBL18512285 0.75 HPGD (0.44) LMNASMN1; SMN2KMT2AHPGDMAPT
SCHEMBL14448664 0.74 HPGD (0.47) LMNASMN1; SMN2KMT2AHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
EP-1979355-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP disclosed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS PPARD, PPARG, PPARA LMNA 2231/4885SMN1; SMN2 3127/4885KMT2A 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.